Pirfenidone in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial was conducted in Japanese patients with well-defined IPF to determine the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 weeks. Of 275 patients randomised (high-dose, 1,800 mg·day −1 ; low-dose, 1,200 mg·day −1 ; or placebo groups in the ratio 2:1:2), 267 patients were evaluated for the efficacy of pirfenidone. Prior to unblinding, the primary end-point was revised; the change in vital capacity (VC) was assessed at week 52. Secondary end-points included the progression-free survival (PFS) time. Significant differences were observed in VC decline (primary end-point) between the placebo group (-0.16 L) and the high-dose group (-0.09 L) (p = 0.0416); differences between the two groups (p = 0.0280) were also observed in the PFS (the secondary end-point). Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients. Pirfenidone was relatively well tolerated in patients with IPF. Treatment with pirfenidone may decrease the rate of decline in VC and may increase the PFS time over 52 weeks. Additional studies are needed to confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationPrognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 2×
“(1) Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi (2) Dept of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, (3) Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, (4) Fourth Dept of Internal Medicine, Nippon Medical School, T…”
BackgroundHigh-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Self-citationMinimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652 · cited 2×
“In cases AFFILIATIONS *Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, #Dept of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, "Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, +Fourth Dept of Internal Medicine, Nippon Medica…”
BackgroundSelf-citationFibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Latsi, P. I., du Bois, R. M., Nicholson, A. G., Colby, T. V., Bisirtzoglou, D., Nikolakopoulou, A., Veeraraghavan, S., Hansell, D. M., & Wells, A. U. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1245oc · Cited by 583
Role of Epithelial Cells in Idiopathic Pulmonary Fibrosis: From Innocent Targets to Serial Killers
Selman, M., & Pardo, A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-003tk · Cited by 529
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, K. R., Mumford, J. A., Murray, S., Kazerooni, E. A., Gross, B. H., Colby, T. V., Travis, W. D., Flint, A., Toews, G. B., Lynch, J. P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1112oc · Cited by 513
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Self-citationRAGHU, G., CRAIG JOHNSON, W., LOCKHART, D., & MAGETO, Y. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.4.9805017 · Cited by 468
Self-citationOku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 436
Zappala, C. J., Latsi, P. I., Nicholson, A. G., Colby, T. V., Cramer, D., Renzoni, E. A., Hansell, D. M., du Bois, R. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00155108 · Cited by 372
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Self-citationDeterminants of survival in idiopathic pulmonary fibrosis.
Schwartz, D. A., Helmers, R. A., Galvin, J. R., Van Fossen, D. S., Frees, K. L., Dayton, C. S., Burmeister, L. F., & Hunninghake, G. W. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.2.8306044 · Cited by 340
Six-Minute Walk, Maximal Exercise Tests: Reproducibility in Fibrotic Interstitial Pneumonia
Eaton, T., Young, P., Milne, D., & Wells, A. U. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-578oc · Cited by 274
King, T. E., Safrin, S., Starko, K. M., Brown, K. K., Noble, P. W., Raghu, G., & Schwartz, D. A. (2005) · Chest · doi:10.1378/chest.127.1.171 · Cited by 222
Self-citationEffect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome
Gahl, W. A., Brantly, M., Troendle, J., Avila, N. A., Padua, A., Montalvo, C., Cardona, H., Anton Calis, K., & Gochuico, B. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00044-6 · Cited by 203
Crystal, R. G., Bitterman, P. B., Mossman, B., Schwarz, M. I., Sheppard, D., Almasy, L., Chapman, H. A., Friedman, S. L., King, T. E., Leinwand, L. A., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2201069 · Cited by 181
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35110-9 · Cited by 181
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38125-x · Cited by 179
Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals
Misra, H. P., & Rabideau, C. L. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007023532508 · Cited by 135
NAGAI, S., HAMADA, K., SHIGEMATSU, M., TANIYAMA, M., YAMAUCHI, S., & IZUMI, T. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.1118 · Cited by 131
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Metadata
- Authors
- Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., Takeuchi, M., Raghu, G., Kudoh, S., Nukiwa, T., & the Pirfenidone Clinical Study Group in Japan
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2009-12-08
- Volume
- 35
- Issue
- 4
- Pages
- 821-829
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4296612182
- Cited by
- 946
- References
- 26
- FWCI
- 33.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.